Apellis Pharmaceuticals Unveils New Data on SYFOVRE® Efficacy at ASRS Meeting, Highlighting Treatment Advances for Geographic Atrophy

Reuters

07-15

Apellis Pharmaceuticals Unveils New Data on SYFOVRE® Efficacy at ASRS Meeting, Highlighting Treatment Advances for Geographic Atrophy

Apellis Pharmaceuticals Inc. has announced that five abstracts related to its drug SYFOVRE® (pegcetacoplan injection) have been accepted for oral presentation at the upcoming American Society of Retina Specialists (ASRS) Annual Scientific Meeting. The meeting is scheduled to take place from July 30 to August 2 in Long Beach, California. The presentations will highlight the efficacy and safety profile of SYFOVRE for patients with geographic atrophy (GA) secondary to age-related macular degeneration $(AMD)$. The data, to be presented by various specialists, will cover topics including baseline characteristics associated with GA progression, the impact of early versus delayed treatment, and the clinical utility of fellow eye data in bilateral GA cases. Additionally, a descriptive analysis of patients treated with pegcetacoplan and anti-VEGF, as well as the impact of AREDS oral micronutrient supplementation, will be discussed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apellis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9494313-en) on July 15, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2551690991"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2551690991\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2551690991?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-15 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2551690991","market":"us","top_or_hot":-1,"title":"Apellis Pharmaceuticals Unveils New Data on SYFOVRE® Efficacy at ASRS Meeting, Highlighting Treatment Advances for Geographic Atrophy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Apellis Pharmaceuticals Unveils New Data on SYFOVRE® Efficacy at ASRS Meeting, Highlighting Treatment Advances for Geographic Atrophy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/APLS\">Apellis Pharmaceuticals Inc.</a> has announced that five abstracts related to its drug SYFOVRE® (pegcetacoplan injection) have been accepted for oral presentation at the upcoming American Society of Retina Specialists (ASRS) Annual Scientific Meeting. The meeting is scheduled to take place from July 30 to August 2 in Long Beach, California. The presentations will highlight the efficacy and safety profile of SYFOVRE for patients with geographic atrophy (GA) secondary to age-related macular degeneration <a href=\"https://laohu8.com/S/AMD\">$(AMD)$</a>. The data, to be presented by various specialists, will cover topics including baseline characteristics associated with GA progression, the impact of early versus delayed treatment, and the clinical utility of fellow eye data in bilateral GA cases. Additionally, a descriptive analysis of patients treated with pegcetacoplan and anti-VEGF, as well as the impact of AREDS oral micronutrient supplementation, will be discussed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apellis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9494313-en) on July 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apellis Pharmaceuticals Unveils New Data on SYFOVRE® Efficacy at ASRS Meeting, Highlighting Treatment Advances for Geographic Atrophy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApellis Pharmaceuticals Unveils New Data on SYFOVRE® Efficacy at ASRS Meeting, Highlighting Treatment Advances for Geographic Atrophy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-15 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Apellis Pharmaceuticals Unveils New Data on SYFOVRE® Efficacy at ASRS Meeting, Highlighting Treatment Advances for Geographic Atrophy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/APLS\">Apellis Pharmaceuticals Inc.</a> has announced that five abstracts related to its drug SYFOVRE® (pegcetacoplan injection) have been accepted for oral presentation at the upcoming American Society of Retina Specialists (ASRS) Annual Scientific Meeting. The meeting is scheduled to take place from July 30 to August 2 in Long Beach, California. The presentations will highlight the efficacy and safety profile of SYFOVRE for patients with geographic atrophy (GA) secondary to age-related macular degeneration <a href=\"https://laohu8.com/S/AMD\">$(AMD)$</a>. The data, to be presented by various specialists, will cover topics including baseline characteristics associated with GA progression, the impact of early versus delayed treatment, and the clinical utility of fellow eye data in bilateral GA cases. Additionally, a descriptive analysis of patients treated with pegcetacoplan and anti-VEGF, as well as the impact of AREDS oral micronutrient supplementation, will be discussed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apellis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9494313-en) on July 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1093756168.USD","symbol_name":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250715:nNDL9lv1Ys:1","article_id":"2551690991","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2551690991","pubTimestamp":1752577257,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Apellis Pharmaceuticals Unveils New Data on SYFOVRE Efficacy at ASRS Meeting, Highlighting Treatment Advances for Geographic Atrophy. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apellis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on July 15, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4505":"高瓴资本持仓","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4139":"生物科技","APLS":"Apellis Pharmaceuticals Inc.","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","NDAQ":"纳斯达克OMX交易所","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC"},"translate_title":"Apellis Pharmaceuticals公布SYFOVRE新数据®ASRS会议上的疗效，强调地理萎缩的治疗进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APLS":0.9,"NDAQ":0.9},"content_text":"Apellis Pharmaceuticals Unveils New Data on SYFOVRE® Efficacy at ASRS Meeting, Highlighting Treatment Advances for Geographic Atrophy\n    \n\nApellis Pharmaceuticals Inc. has announced that five abstracts related to its drug SYFOVRE® (pegcetacoplan injection) have been accepted for oral presentation at the upcoming American Society of Retina Specialists (ASRS) Annual Scientific Meeting. The meeting is scheduled to take place from July 30 to August 2 in Long Beach, California. The presentations will highlight the efficacy and safety profile of SYFOVRE for patients with geographic atrophy (GA) secondary to age-related macular degeneration $(AMD)$. The data, to be presented by various specialists, will cover topics including baseline characteristics associated with GA progression, the impact of early versus delayed treatment, and the clinical utility of fellow eye data in bilateral GA cases. Additionally, a descriptive analysis of patients treated with pegcetacoplan and anti-VEGF, as well as the impact of AREDS oral micronutrient supplementation, will be discussed.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apellis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9494313-en) on July 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}